ガン治療における新しい時代:プロテアソーム-Bcl-2軸を標的とする
Sourabh Soni1, Vandana Anang1, Yutong Zhao1,2
1Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Davis Heart and Lung Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Journal of experimental & clinical cancer research : CR
|August 22, 2025
まとめ
Dysregulated B細胞リンパ腫-2 (Bcl-2) タンパク質は癌に影響する. Ubiquitin-proteasome system (UPS) は,Bcl-2のレベルを制御し,治療目標を提供している. このレビューは,がんの進行と治療におけるプロテアソーム-Bcl-2軸を調査しています.
科学分野:
- 分子生物学
- 癌 生物学
- 生物化学
背景:
- B細胞リンパ腫-2 (Bcl-2) 族のタンパク質はアポトーシスを調節し,がんではしばしば制御不能になり,細胞の生存を促進します.
- Ubiquitin-proteasomeシステム (UPS) は,Bcl-2ファミリーを含むタンパク質の安定性を制御するために不可欠です.
- UPS- Bcl-2の相互作用の調節不良は癌の進行に寄与する.
研究 の 目的:
- プロテアソームとBcl-2ファミリータンパク質の複雑な関係を見直す.
- プロテアソーム媒介による分解が 癌細胞の生存と増殖にどのように影響するか調べる
- ガン治療におけるプロテアソーム-Bcl-2軸を標的とした治療の可能性について議論する.
主な方法:
- ユビキチン- プロテアソームシステムとBcl-2ファミリータンパク質の相互作用に焦点を当てた文献レビュー.
- 細胞生存と増殖に影響を与えるプロテアソーム媒介の分解機構の分析.
- 抗がん剤としてのプロテアソーム阻害剤の検討と,その臨床的応用
主要な成果:
- Bcl-2タンパク質のプロテアソーム媒介の分解は,アポトーシスと細胞生存を調節する重要な要因である.
- プロテアソーム-Bcl-2軸を標的にすることは,様々な癌に対する有望な治療戦略です.
- プロテアソーム阻害剤は臨床的有効性を示しているが,限界にも直面している.
結論:
- プロテアソームとBcl-2タンパク質の間の複雑な結合は,がんの発症において重要な役割を果たします.
- この軸をターゲットにすることで 新しいがん治療の 実行可能な戦略が得られます
- 現在のプロテアソーム阻害剤の限界を克服するためのさらなる研究は,がん治療の進歩に不可欠です.
関連する概念動画
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
The Intrinsic Apoptotic Pathway
6.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
The Proteasome
1.1K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.1K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K


